-
1.
公开(公告)号:WO2013142124A1
公开(公告)日:2013-09-26
申请号:PCT/US2013030267
申请日:2013-03-11
Applicant: VERTEX PHARMA
Inventor: KULDIPKUMAR ANUJ K , MEDEK ALES , FERRIS LORI ANN , MUDUNURI PRAVEEN , JUNG YOUNG CHUN , WILLCOX DAVID RICHARD , WALDO MICHAEL , NUGENT WILLIAM ALOYSIUS
IPC: C07H19/06 , A61K31/7072 , A61P31/14
CPC classification number: C07H19/10 , A61K31/7056 , A61K31/706 , A61K31/7064 , A61K31/7068 , A61K31/7072 , A61K38/00 , A61K45/06 , C07B2200/13 , C07H19/06 , A61K2300/00
Abstract: The present application relates to solid state forms, for example, crystalline forms of 2'- C-methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate, pharmaceutical compositions that can include one or more solid forms of 2'-C-methyluridine-5'- (0-phenyl-N-(S)-1-(isopropoxycarbonyl)ethyl)thiophosphoramidate, and methods of treating or ameliorating diseases and/or conditions with one or more solid forms of 2'-C-methyluridine-5'- (O-phenyl-N-(S)- 1 -(isopropoxy carbonyl)ethyl)thiophosphoramidate. Also disclosed herein are methods of treating diseases and/or conditions with one or more solid forms of 2'-C- methyluridine-5 '-(O-phenyl-N-(S)- 1 -(isopropoxycarbonyl)ethyl)thiophosphoramidate in combination with one or more other agents.
Abstract translation: 本申请涉及固体形式,例如2'-C-甲基尿苷-5' - (O-苯基-N-(S)-1-(异丙氧基羰基)乙基)硫代磷酰胺的结晶形式,可以包括 一种或多种固体形式的2'-C-甲基尿苷-5'-(O-苯基-N-(S)-1-(异丙氧基羰基)乙基)硫代氨基磷酸酯,以及用一种或多种硫代磷酸酰胺酯治疗或改善疾病和/或病症的方法 更多固体形式的2'-C-甲基尿苷-5'-(O-苯基-N-(S)-1-(异丙氧基羰基)乙基)硫代磷酰胺。 本文还公开的是使用一种或多种固体形式的2'-C-甲基尿苷-5' - (O-苯基-N-(S)-1-(异丙氧基羰基)乙基)硫代磷酰胺的组合治疗疾病和/或病症的方法 与一个或多个其他代理。
-
公开(公告)号:MX387720B
公开(公告)日:2025-03-12
申请号:MX2016013301
申请日:2016-10-10
Applicant: VERTEX PHARMA
Inventor: MEDEK ALES , PHENIX BRIAN DEAN , KNEZIC DRAGUTIN , DOKOU ELENI , BRODEUR GEOFFREY GLEN , MCCARTY KATIE LYNN , BAGNOL LAURENT JEAN- CLAUDE , FERRIS LORI ANN , CHANDRAN SACHIN , WAGGENER SARA A
IPC: A61K45/06 , A61K9/14 , A61K9/16 , A61K9/20 , A61K31/404 , A61K31/47 , C07D209/04 , C07D215/00
Abstract: La presente invención presenta una composición que comprende una pluralidad de agentes terapéuticos en donde la presencia de un agente terapéutico mejora las propiedades de al menos otro agente terapéutico. En una modalidad, los agentes terapéuticos son reguladores de conductancia de transmembrana de fibrosis Quísticas (CFTR) tal como un corrector CFTR o potenciador CFTR para el tratamiento de enfermedades mediadas por el CFTR, tal como fibrosis Quística. También se describen sus métodos y kits.
-
公开(公告)号:CA2944140C
公开(公告)日:2022-10-04
申请号:CA2944140
申请日:2015-04-14
Applicant: VERTEX PHARMA
Inventor: PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , KNEZIC DRAGUTIN , MCCARTY KATIE LYNN , MEDEK ALES , WAGGENER SARA A
IPC: A61K9/14 , A61K31/404 , A61K31/47 , A61P43/00
Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
-
公开(公告)号:ES2885181T3
公开(公告)日:2021-12-13
申请号:ES18173500
申请日:2015-04-14
Applicant: VERTEX PHARMA
Inventor: PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , KNEZIC DRAGUTIN , MCCARTY KATIE LYNN , MEDEK ALES , WAGGENER SARA A
IPC: A61K45/06 , A61K9/14 , A61K9/16 , A61K9/20 , A61K31/404 , A61K31/47 , C07D209/04 , C07D215/00
Abstract: Una dispersión secada por pulverización que comprende (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-N-(1-(2,3- dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1H-indol-5-il)ciclopropanocarboxamida (Compuesto 1) y N-(5- hidroxi-2,4-di-terc-butil-fenil-4-oxo-1H-quinolina-3-carboxamida (Compuesto 2), en donde la dispersión secada por pulverización es sustancialmente amorfa y comprende menos de aproximadamente el 15 % de cristalinidad.
-
公开(公告)号:RS57476B9
公开(公告)日:2021-10-29
申请号:RSP20180880
申请日:2015-04-14
Applicant: VERTEX PHARMA
Inventor: PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , KNEZIC DRAGUTIN , MCCARTY KATIE LYNN , MEDEK ALES , WAGGENER SARA A
IPC: A61K45/06 , A61K9/14 , A61K9/16 , A61K9/20 , A61K31/404 , A61K31/47 , C07D209/04 , C07D215/00
-
公开(公告)号:UA124567C2
公开(公告)日:2021-10-13
申请号:UAA201611464
申请日:2015-04-14
Applicant: VERTEX PHARMA
Inventor: PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , KNEZIC DRAGUTIN , MCCARTY KATIE LYNN , MEDEK ALES , WAGGENER SARA A
Abstract: Винахідстосуєтьсяфармацевтичноїкомбінації, якамістить: першувисушенурозпиленнямдисперсіюі другувисушенурозпиленнямдисперсію, депершависушенарозпиленнямдисперсіяміститьвідприблизно 70 % мас. доприблизно 90 % мас. аморфного (R)-1-(2,2-дифторбензо[d][1,3]діоксол-5-іл)-N-(1-(2,3-дигідроксипропіл)-6-фтор-2-(1-гідрокси-2-метилпропан-2-іл)-1H-індол-5-іл)циклопропанкарбоксаміду (сполука 1) івідприблизно 10 % мас. доприблизно 30 % мас. полімеру, дедругависушенарозпиленнямдисперсіяміститьаморфний N-[2,4-біс(1,1-диметилетил)-5-гідроксифеніл]-1,4-дигідро-4-оксохінолін-3-карбоксамід (сполука 2); ідевказанафармацевтичнакомбінаціяявляєсобоютаблетку.
-
公开(公告)号:AU2018351533A8
公开(公告)日:2020-05-07
申请号:AU2018351533
申请日:2018-10-19
Applicant: VERTEX PHARMA
Inventor: DHAMANKAR VARSHA , DINEHART KIRK RAYMOND , DOKOU ELENI , FERRIS LORI ANN , GOPINATHAN NISHANTH , MCCARTY KATIE , METZLER CATHERINE , ZHANG BEILI , CHEN WEICHAO GEORGE , HASELTINE ERIC L , MOSKOWITZ SAMUEL , ROBERTSON SARAH , WALTZ DAVID
IPC: C07D401/14 , A61K31/4439 , A61P11/00
Abstract: Crystalline Forms of Compound (I): (Formula (I)) and pharmaceutically acceptable salts thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.
-
公开(公告)号:CL2019001553A1
公开(公告)日:2020-04-03
申请号:CL2019001553
申请日:2019-06-06
Applicant: VERTEX PHARMA
Inventor: FERRIS LORI ANN , ANDERSON COREY , CLEVELAND THOMAS , KHATUYA HARIPADA , MCCARTNEY JASON , UY JOHNNY , ZHOU JINGLAN , ALCACIO TIMOTHY , BAEK MINSON , KESHAVARZ-SHOKRI ALI , PARASELLI PRASUNA , GULEVICH ANTON , HADIDA RUAH SARA SABINA , HSIA CLARA KUANG-JU , HUGHES ROBERT M , JOSHI PRAMOD VIRUPAX , KANG PING , KRENITSKY PAUL JOHN , MILLER MARK THOMAS , PIERRE FABRICE JEAN DENIS , SHI YI , SHRESTHA MUNA , SIESEL DAVID ANDREW , STAVROPOULOS KATHY , TERMIN ANDREAS P , VAN GOOR FREDRICK F , YOUNG TOMOTHY JOHN , ABELA ALEXANDER RUSSELL , ANGELL PAUL TIMOTHY , CLEMENS JEREMY J , GROOTENHUIS PETER DIEDERIK JAN , GROSS RAYMOND STANLEY
IPC: C07D231/20 , A61K31/455 , A61P11/00 , C07D401/04 , C07D401/14
Abstract: COMPUESTOS HETEROCÍCLICOS MODULADOR DEL REGULADOR DE CONDUCTANCIA TRANSMEMBRANA DE FIBROSIS QUÍSTICA; COMPOSICIONES FARMACÉUTICAS; PROCESO PARA PREPARAR EL MODULADOR; FORMAS CRISTALINAS Y USO EN EL TRATAMIENTO DE LA FIBROSIS QUÍSTICA.
-
公开(公告)号:AU2015247850B2
公开(公告)日:2019-07-18
申请号:AU2015247850
申请日:2015-04-14
Applicant: VERTEX PHARMA
Inventor: PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , CHANDRAN SACHIN , DOKOU ELENI , FERRIS LORI ANN , KNEZIC DRAGUTIN , MCCARTY KATIE LYNN , MEDEK ALES , WAGGENER SARA A
IPC: A61K9/14 , A61K9/16 , A61K9/20 , A61K31/404 , A61K31/47 , A61K45/06 , C07D209/04 , C07D215/00
Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
-
公开(公告)号:MA46476B1
公开(公告)日:2021-07-29
申请号:MA46476
申请日:2015-04-14
Applicant: VERTEX PHARMA
Inventor: CHANDRAN SACHIN , DOKOU ELENI , KNEZIC DRAGUTIN , MEDEK ALES , PHENIX BRIAN DEAN , BAGNOL LAURENT JEAN-CLAUDE , BRODEUR GEOFFREY GLEN , FERRIS LORI ANN , MCCARTY KATIE LYNN , WAGGENER SARA A
IPC: A61K31/404 , A61K9/14 , A61K9/16 , A61K9/20 , A61K31/47 , A61K45/06 , C07D209/04 , C07D215/00
Abstract: La présente invention concerne des compositions comprenant une pluralité d'agents thérapeutiques dans lesquelles la présence d'un agent thérapeutique améliore les propriétés d'au moins un autre agent thérapeutique. Dans un mode de réalisation, les agents thérapeutiques sont des régulateurs de la conductance transmembranaire de la mucoviscidose (cftr) tels qu'un correcteur cftr ou un potentialisateur cftr pour le traitement de maladies à médiation par cftr telles que la mucoviscidose. L'invention concerne également des procédés et des kits correspondants.
-
-
-
-
-
-
-
-
-